Tempus AI, Inc. (TEM)
NASDAQ: TEM · Real-Time Price · USD
73.25
-3.05 (-4.00%)
Aug 27, 2025, 4:00 PM - Market closed

Company Description

Tempus AI, Inc. operates as a healthcare technology company.

It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties.

The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies.

In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data.

The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology, as well as strategic collaboration with Personalis, Inc. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023.

Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Tempus AI, Inc.
Tempus AI logo
CountryUnited States
Founded2015
IPO DateJun 14, 2024
IndustryHealth Information Services
SectorHealthcare
Employees2,400
CEOEric Lefkofsky

Contact Details

Address:
600 West Chicago Avenue, Suite 510
Chicago, Illinois 60654
United States
Phone800 976 5448
Websitetempus.com

Stock Details

Ticker SymbolTEM
ExchangeNASDAQ
Stock TypeCommon Stock
Share ClassClass A Shares
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$37.00
CIK Code0001717115
CUSIP Number71535D106
ISIN NumberUS88023B1035
Employer ID47-4903308
SIC Code7370

Key Executives

NamePosition
Eric P. Lefkofsky J.D.Co-Founder, Chief Executive Officer, President and Chairman
Ryan FukushimaChief Operating Officer
Ryan M. Bartolucci CPAChief Accounting Officer
Shane ColleyChief Technology Officer
Dr. Kate A. Sasser Ph.D.Chief Scientific Officer
Erik PhelpsExecutive Vice President, Assistant Secretary and Chief Administrative and Legal Officer
Elizabeth KrutoholowVice President of Investor Relations and Competitive Intelligence
Patty SpillerChief Marketing Officer
Christina AntoniouSenior Vice President and Head of Corporate Development
Stacey KraftChief People Officer

Latest SEC Filings

DateTypeTitle
Aug 26, 2025144Filing
Aug 20, 2025144Filing
Aug 20, 2025144Filing
Aug 20, 2025144Filing
Aug 20, 2025144Filing
Aug 19, 2025144Filing
Aug 19, 2025144Filing
Aug 18, 2025DEF 14CFiling
Aug 18, 2025144Filing
Aug 8, 2025PRE 14CFiling